{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:26:27Z","timestamp":1792009587937,"version":"4.4.0"},"reference-count":0,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypophosphatemic rickets\/osteomalacia with inappropriately low serum 1,25-dihidroxyvitamin D level is commonly observed in X-linked hypophosphatemic rickets\/osteomalacia, autosomal dominant hypophosphatemic rickets\/osteomalacia and tumor-induced osteomalacia. Although the involvement of a newly identified factor, FGF-23, in the pathogenesis of ADHR and TIO has been suggested, clinical evidence indicating the role of FGF-23 has been lacking. We have previously shown that FGF-23 is cleaved between Arg179 and Ser180, and this processing abolished biological activity of FGF-23 to induce hypophosphatemia. Therefore, sandwich ELISA for biologically active intact human FGF-23 was developed using two kinds of monoclonal antibodies that requires the simultaneous presence of both the N-terminal and C-terminal portion of FGF-23. The serum levels of FGF-23 in healthy adults were measurable and ranged from 8.2 to 54.3 ng\/L. In contrast, those in a patient with TIO were over 200 ng\/L. After the resection of the responsible tumor, the elevated FGF-23 level returned to normal level within 1 h. The increase of serum concentrations of 1,25-dihidroxyvitamin D and phosphate, and the decrease of serum 24,25-dihydroxyvitamin D followed the change of FGF-23. In addition, the elevated serum FGF-23 levels were demonstrated in most patients with XLH. It is likely that increased serum levels of FGF-23 contributes to the development of hypophosphatemia not only in TIO but also in XLH.<\/jats:p>","DOI":"10.1210\/jc.2002-021105","type":"journal-article","created":{"date-parts":[[2002,11,2]],"date-time":"2002-11-02T03:22:01Z","timestamp":1036207321000},"page":"4957-4960","source":"Crossref","is-referenced-by-count":583,"title":["Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets\/Osteomalacia"],"prefix":"10.1210","volume":"87","author":[{"given":"Yuji","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Pharmaceutical Research Labs, KIRIN Brewery Co. Ltd. (Y.Y., T.Y.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Third Department of Medicine, Teikyo University School of Medicine (R.O., M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minako","family":"Shibata","sequence":"additional","affiliation":[{"name":"Third Department of Medicine, Teikyo University School of Medicine (R.O., M.S.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Endocrinology, Metabolism and Genetics Unit, Tokyo Metropolitan Kiyose Children\u2019s Hospital (Y.H.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Satoh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University School of Medicine (K.S., T.T.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Tajima","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Hokkaido University School of Medicine (K.S., T.T.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Tokyo School of Medicine (Y.T., T.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Tokyo School of Medicine (Y.T., T.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Tokyo Hospital (K.N., S.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeyoshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Labs, KIRIN Brewery Co. Ltd. (Y.Y., T.Y.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University of Tokyo Hospital (K.N., S.F.)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/11\/4957\/9040802\/jcem4957.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/87\/11\/4957\/9040802\/jcem4957.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T03:05:45Z","timestamp":1594955145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/87\/11\/4957\/2823148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,1]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2002-021105","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11,1]]}}}